Clinical Trials Sponsored by UnitedHealth Group

Total 7314 results

RECORDATI GROUP

Terminated

Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH

Lower Urinary Tract Symptoms

Spain, United Kingdom, Italy, Germany, Poland
RECORDATI GROUP

Active, not recruiting

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Cushing's Syndrome

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, China, Costa Rica, France, Germany, India, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Thailand, Turkey
Raisio Group

Completed

Lipid Lowering Effect of Plant Stanol Ester in a Spoonable Non-dairy Product

Hypercholesterolemia

Finland
TauTona Group

Withdrawn

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment (D-SCOUT)

Sickle Cell Disease | Chronic Cutaneous Ulcer

United States
RECORDATI GROUP

Completed

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Neurogenic Detrusor Overactivity

Czechia, France, Poland, Portugal
Polaris Group

Terminated

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (TRAP)

Glioma | Hepatocellular Carcinoma | Uveal Melanoma | Sarcomatoid Carcinoma | Pleural Mesothelioma Malignant Advanced | Peritoneal Mesothelioma Malignant Advanced | Non-squamous Non-small Cell Lung Carcinoma

United States, United Kingdom
Polaris Group

Terminated

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Acute Myeloid Leukemia

Taiwan
InQpharm Group

Completed

Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea

Diarrhoea

Germany
InQpharm Group

Completed

Efficacy and Safety of Litramine in 1 Year Weight Loss Study

Weight Loss | Overweight and Obesity | Obesity; Excess Calories

Germany
Polaris Group

Completed

PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy

Non-Hodgkin's Lymphoma

Taiwan
InQpharm Group

Completed

Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others

Upper Respiratory Tract Symptoms

Germany
Menarini Group

Terminated

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-4)

Irritable Bowel Syndrome With Diarrhea

Germany, Sweden, United States, United Kingdom, Hungary, Poland, Latvia, Slovakia, Czech Republic
Menarini Group

Completed

Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride (DAVID lap)

Acute Pain

Romania, Poland, Hungary, Latvia, Lithuania, Russian Federation, Slovakia, Spain
Polaris Group

Completed

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

Hepatocellular Carcinoma

United States
Polaris Group

Completed

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors

Taiwan, United States
InQpharm Group

Completed

Efficacy and Safety of IQP-VV-102 in Weight Management

Obesity | Overweight

Germany
InQpharm Group

Completed

Litramine in Weight Maintenance

Overweight | Obese | Weight Maintenance

Germany
InQpharm Group

Completed

IQP-CL-101 in IBS Management

Irritable Bowel Syndrome

Germany
Virchow Group

Completed

Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis

Osteoporosis

India
Virchow Group

Completed

Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia

Hyperuricemia

India
Menarini Group

Completed

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies (FLORENCE)

Tumor Lysis Syndrome
Menarini Group

Completed

Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion (RAFFAELLO)

Persistent Atrial Fibrillation

Germany, Italy, Spain, United Kingdom
InQpharm Group

Completed

IQP-PO-101 for the Regulation of Bowel Movement Frequency

Constipation | Irregular Bowel Movement Frequency

Germany
Raisio Group

Completed

Lipid-lowering Effect of Plant Stanol Yogurt

Dyslipidemias | Hypercholesterolemia | Hyperlipidemias

Turkey
InQpharm Group

Completed

Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Postprandial Heartburn

Germany
Menarini Group

Completed

A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS (ALBATROSS)

Osteoarthritis, Knee

Germany, France, Italy, Spain
Menarini Group

Withdrawn

Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant With Colic Not Responding to Conventional Treatment (nocry-a)

Infantile Colic
Menarini Group

Terminated

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)

Ovarian Cancer

United States, Spain, Germany, Belgium, France, Czech Republic, Hungary, Italy, Poland
RECORDATI GROUP

Completed

Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH

Benign Prostatic Hyperplasia

United Kingdom
Evolutec Group

Unknown

Safety and Efficacy Study of rEV131 in Allergic Rhinitis

Hay Fever

United States
Ascentage Pharma Group Inc.
Tanner Pharma Group

Available

Named Patient Program for Olverembatinib (HQP1351)
Groupe Oncologie Radiotherapie Tete et Cou
Tumor Study Group Head and Neck

Completed

Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation

Larynx Cancer | Hypopharynx Cancer

France
Jordan Collaborating Cardiology Group
Cardiovascular Academy Group

Terminated

Myocardial Infarction Triggers and Onset in Jordan Study 2 (MINTOR 2)

Triggers of Acute Myocardial Infarction | Time of Onset of Acute Myocardial Infarction | Long-term Prognosis After Acute Myocardial Infarction

Jordan
NCIC Clinical Trials Group
Southwest Oncology Group; Cancer and Leukemia Group B; North Central Cancer Treatment...

Completed

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Breast Cancer

Canada, United States
AstraZeneca
Gynecologic Oncology Group Foundation; European Network for Gynaecological...

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical)

Locally Advanced Cervical Cancer

Spain, Denmark, Korea, Republic of, Italy, Japan, Peru, China, Brazil, Taiwan, United States, Canada, Turkey, India, Poland, Mexico, Puerto Rico, Norway
UNICANCER
Canadian Cancer Trials Group; GONO GROUP

Active, not recruiting

IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting (IROCAS)

Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)

France, Canada
Cancer Research Group - Collaborative Group, Beirut...

Unknown

Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca (TNM)

Breast Cancer

Lebanon
Bistro Study Group
Barts & The London NHS Trust; Groupe Hospitalier Pitie-Salpetriere

Completed

Biomarkers In Seizure To Predict Recurrence and Severe Outcomes (BISTRO)

Seizures | Copeptin | S-100b Protein

France, United Kingdom
NCIC Clinical Trials Group
Eastern Cooperative Oncology Group

Completed

Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

Hodgkin Lymphoma

Canada, United Kingdom, Italy
NCIC Clinical Trials Group
North Central Cancer Treatment Group

Completed

Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease

Colorectal Cancer

United States
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
NCIC Clinical Trials Group
Australasian Gastro-Intestinal Trials Group

Completed

Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

Quality of Life | Colorectal Cancer

Canada, Australia
NCIC Clinical Trials Group

Completed

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Breast Cancer

Canada
NCIC Clinical Trials Group

Completed

Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer

Head and Neck Cancer

Canada
NCIC Clinical Trials Group

Terminated

Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer

Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

Canada
NCIC Clinical Trials Group

Completed

Radiation in Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Cancer

Canada
NCIC Clinical Trials Group

Terminated

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Bladder Cancer

Canada
NCIC Clinical Trials Group

Completed

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Prostate Cancer

Canada
NCIC Clinical Trials Group

Completed

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Canada, Singapore, Australia, Romania, Argentina, Brazil
NCIC Clinical Trials Group

Completed

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Kidney Cancer | Breast Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer

Clinical Trials Sponsored by UnitedHealth Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations